

(10-2003)
10 CFR 2.201

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:

Oakland/Macomb Internal Medicine Gp, PC
43184 Dequindre Road
Suite 201
Sterling Heights, MI 48314

2. NRC/REGIONAL OFFICE

UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION III
2443 WARRENVILLE ROAD, SUITE 210
LISLE, IL 60532-4352

REPORT 2006-001

3. DOCKET NUMBER(S)
030-36936

4. LICENSEE NUMBER(S)
21-32575-01

5. DATE(S) OF INSPECTION
March 9, 2006

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

- 1. Based on the inspection findings, no violations were identified.
- 2. Previous violation(s) closed.
- 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, NUREG-1600, to exercise discretion, were satisfied.

----- Non-Cited Violation(s) was/were discussed involving the following requirement(s) and Corrective Action(s):

- 4. During this inspection certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.

(Violations and Corrective Actions)

Licensee's Statement of Corrective Actions for Item 4, above.

I hereby state that, within 30 days, the actions described by me to the inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

Title	Printed Name	Signature	Date
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Robert P. Hays		3/09/06

DN

**Docket File Information
SAFETY INSPECTION REPORT
AND COMPLIANCE INSPECTION**

1. LICENSEE Oakland/Macomb Internal Medicine Gp, PC		2. NRC/REGIONAL OFFICE Region III	
REPORT NUMBER(S) 2006-001			
3. DOCKET NUMBER(S) 03036936	4. LICENSE NUMBER(S) 21-32575-01	5. DATE(S) OF INSPECTION March 9, 2006	
6. INSPECTION PROCEDURES USED 87130	7. INSPECTION FOCUS AREAS 03.01 - 03.07		
SUPPLEMENTAL INSPECTION INFORMATION			
1. PROGRAM CODE(S) 02201	2. PRIORITY 5	3. LICENSEE CONTACT Office Manager	4. TELEPHONE NUMBER 586/739-1333
<input checked="" type="checkbox"/> Main Office Inspection		Next Inspection Date: March 2011	
<input type="checkbox"/> Field Office			
<input type="checkbox"/> Temporary Job Site			

PROGRAM SCOPE

The licensee was a medical clinic located in Sterling Heights, MI, and authorized by the license to use any byproduct material except aerosols and generators as needed permitted by 10 CFR 35.200, excluding xenon-133 for any imaging and localization studies. Licensed activities were conducted in the nuclear medicine/cardiac stress test/scanning rooms at the authorized location as indicated on the license. Four cardiac perfusion nuclear medicine studies/scans were scheduled and conducted by four alternating contract nuclear medicine technologists every other Wednesday using Cardiolite® only. The licensee received unit doses as ordered from a local nuclear pharmacy. All waste was held for decay-in-storage (DIS) or returned to the nuclear pharmacy as a limited quantity shipment. Licensed activities began on July 18, 2005.

Performance Observations

At the time of the inspection, no licensed activities were scheduled, no NMTs were onsite, nor available. A records review included: (1) area surveys and survey meter use; (2) package check-in procedures and wipe test counts; (3) dosimetry; (4) dose calibrator checks; (5) security; and (6) consultant audits, with no issues noted.